Toronto Dominion Bank Purchases 2,099 Shares of ResMed Inc. (NYSE:RMD)

Toronto Dominion Bank grew its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,349 shares of the medical equipment provider's stock after acquiring an additional 2,099 shares during the quarter. Toronto Dominion Bank's holdings in ResMed were worth $11,743,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Colonial Trust Co SC boosted its stake in shares of ResMed by 6,250.0% in the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 125 shares during the period. Optiver Holding B.V. bought a new stake in ResMed during the fourth quarter worth about $33,000. Itau Unibanco Holding S.A. lifted its holdings in shares of ResMed by 1,000.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 150 shares during the period. OFI Invest Asset Management bought a new stake in shares of ResMed during the 4th quarter worth approximately $39,000. Finally, Coppell Advisory Solutions LLC lifted its holdings in shares of ResMed by 1,750.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 185 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 175 shares during the period. Institutional investors own 54.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. KeyCorp set a $274.00 target price on ResMed in a research note on Thursday, April 24th. Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. Stifel Nicolaus dropped their target price on shares of ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a report on Wednesday, March 5th. Piper Sandler dropped their target price on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a report on Thursday, April 24th. Finally, Mizuho set a $265.00 price objective on shares of ResMed in a research note on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $259.33.

ResMed Trading Down 0.2%

Shares of NYSE:RMD traded down $0.50 during mid-day trading on Friday, hitting $244.62. The company had a trading volume of 1,060,298 shares, compared to its average volume of 1,024,596. The firm has a fifty day moving average price of $230.20 and a 200 day moving average price of $234.21. The company has a market capitalization of $35.87 billion, a PE ratio of 28.88, a price-to-earnings-growth ratio of 1.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed Inc. has a one year low of $179.42 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating the consensus estimate of $2.36 by $0.01. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The company's quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.13 earnings per share. As a group, research analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

Insiders Place Their Bets

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $227.71, for a total value of $455,420.00. Following the completion of the sale, the director now directly owns 75,218 shares of the company's stock, valued at approximately $17,127,890.78. This represents a 2.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $243.23, for a total value of $1,948,029.07. Following the completion of the transaction, the chief executive officer now owns 455,503 shares of the company's stock, valued at $110,791,994.69. This trade represents a 1.73% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,949 shares of company stock valued at $11,822,260. Corporate insiders own 0.71% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.